Vancouver, B.C. and Boston, MA, January 9, 2018 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced today that pursuant to the Company’s Stock Option Plan, an aggregate of 1,000,000 shares have been granted to certain consultants as incentive stock options at an exercise price of $0.26 per share. The options are exercisable for a period of five years, ending on January 9, 2023.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer during minimally invasive surgeries. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imagindev.wpengine.com.
For further information, contact:
Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: [email protected]
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected, except as required under applicable securities legislation; the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
U.S. HQ:
CA HQ:
890 West Pender Street, Suite 600 Vancouver, British Columbia Canada V6C 1J9 778-998-5000 ; 604-687-1327 (fax) 69 Longwood Avenue Hyannis Port, MA 02647 U.S.A. 617-571-6006
